IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Regeneron Pharmaceuticals v Kymab Limited [2017] APO 37
Patent Application: 2011266843
Title:Animal models and therapeutic molecules
Patent Applicant: Kymab Limited
Opponent: Regeneron Pharmaceuticals
Delegate: Dr B. Akhurst
Decision Date: 19 July 2017
Hearing Date: Written submissions filed on 4, 18 and 26 April 2017.
Catchwords: PATENTS – opposition under section 104 – allowability under section 102(2) considered – opposition successful – amendment refused – no award of costs.
Representation: Patent attorney for the applicant: Griffith Hack.
Patent attorney for the opponent: FB Rice.
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2011266843
Title:Animal models and therapeutic molecules
Patent Applicant: Kymab Limited
Date of Decision: 19 July 2017
DECISION
I allow the amendment to the statement of grounds and particulars requested by Regeneron.
The opposition is successful and I refuse the amendments.
I make no award of costs.
REASONS FOR DECISION
Background
Patent application 2011266843 was filed by Kymab Limited (Kymab) on 7 January 2011 under the provisions of the PCT, claiming an earliest priority date of 17 June 2010. The application was advertised as accepted on 30 April 2015.
Regeneron Pharmaceuticals, Inc. (Regeneron) filed a Notice of Opposition to grant of a patent on 30 July 2015 and a statement of grounds and particulars (SGP) on 30 October 2015. Evidence in support, answer and reply in the section 59 opposition was completed by 4 July 2016.
Subsequently, Kymab proposed amendments to the specification under section 104 on 3 August 2016, 7 September 2016 and 25 October 2016. The grant of leave to amend was advertised under reg. 10.5(2) on 8 December 2016. On 8 February 2017, Regeneron filed a Notice of Opposition to allowance of the amendments, followed by a SGP on 8 March 2017. Neither party sought to file evidence in the s 104 opposition, and the matter was set for a hearing by written submissions.
On 4 April 2017, Regeneron requested amendments to its SGP in the s104 opposition and advised, in effect, that it relied on the particulars in the original and subsequently filed SGP for its written submissions in the s104 opposition.
On 18 April 2017, Kymab filed submissions in answer to the matters particularised in the SGP and proposed amendments, and confirmed on 12 May 2017 that it did not object to the SGP amendment request. In the circumstances, I consider it reasonable to allow Regeneron’s request to amend the SGP in the s104 opposition.
Regeneron filed submissions in reply on 26 April 2017.
This decision relates only to Regeneron’s opposition to Kymab’s request to amend the specification under section 104.
Issue estoppel
Kymab’s submissions for the hearing are substantially that, in deciding this matter, I should disregard Regeneron’s submissions where they had already been considered by the examining delegate who granted leave to amend the specification. However, administrative decisions by the Commissioner do not give rise to an issue estoppel and consequently I am not estopped from deciding all of the matters raised in…
Keep reading for free
Create a free CaseChat account to read Regeneron Pharmaceuticals v Kymab Limited and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2017] APO 37
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.